About mavacamten
Cardiac myosin inhibitor
Used for
- Treats adults with symptomatic obstructive hypertrophic cardiomyopathy to improve symptoms and physical function.
Usual adult dose
Usually 2.5 mg by mouth once daily initially; dose is adjusted using heart ultrasound results, up to 15 mg daily.
Common side effects
- Dizziness
- Fainting
- Heart failure symptoms, such as shortness of breath or leg swelling
Important warnings
- Can weaken heart pumping and cause heart failure; heart ultrasound monitoring is required.
- Do not start during pregnancy; effective contraception is required during treatment and for four months afterward.
- Many medicines and supplements affect mavacamten levels; some combinations are contraindicated.
- Available through a restricted safety program in the United States.
Pregnancy
May cause fetal harm. Avoid during pregnancy; use effective contraception during treatment and for four months after stopping.
Breastfeeding
Breastfeeding is not recommended during treatment and for four months after the final dose.
Interactions
- Strong CYP2C19 inhibitors or moderate-to-strong CYP2C19 inducers can cause dangerous changes in drug levels.
- Certain CYP3A4 or CYP2C9 medicines can also affect levels; combinations may be prohibited.
- Some combinations with beta blockers, verapamil, or diltiazem increase heart-failure risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.